MX343135B - Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. - Google Patents
Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.Info
- Publication number
- MX343135B MX343135B MX2012007962A MX2012007962A MX343135B MX 343135 B MX343135 B MX 343135B MX 2012007962 A MX2012007962 A MX 2012007962A MX 2012007962 A MX2012007962 A MX 2012007962A MX 343135 B MX343135 B MX 343135B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- making
- same
- type compounds
- fumagillol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La descripción proporciona un compuesto tipo fumagilol y su uso en el tratamiento de trastornos médicos como obesidad; se proporcionan las composiciones farmacéuticas y los métodos de uso, por ejemplo en el tratamiento de obesidad.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29331810P | 2010-01-08 | 2010-01-08 | |
PCT/US2011/020520 WO2011085201A1 (en) | 2010-01-08 | 2011-01-07 | Fumagillol type compounds and methods of making and using same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012007962A MX2012007962A (es) | 2012-11-21 |
MX343135B true MX343135B (es) | 2016-10-25 |
Family
ID=43838144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012007962A MX343135B (es) | 2010-01-08 | 2011-01-07 | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (3) | US8772333B2 (es) |
EP (1) | EP2521719B1 (es) |
JP (1) | JP5827239B2 (es) |
KR (1) | KR101696960B1 (es) |
CN (1) | CN102791699B (es) |
AU (1) | AU2011204267B2 (es) |
BR (1) | BR112012016793A2 (es) |
CA (1) | CA2786603C (es) |
MX (1) | MX343135B (es) |
WO (1) | WO2011085201A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2278637B2 (en) | 1999-12-01 | 2021-06-09 | The Trustees of Princeton University | Complexes of form L2MX |
WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
DE102010048374A1 (de) | 2010-10-13 | 2012-04-19 | Merck Patent Gmbh | Pyrrolidinone als MetAP-2 Inhibitoren |
WO2012075020A1 (en) * | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
US9707330B2 (en) | 2011-08-22 | 2017-07-18 | Medtronic, Inc. | Dual flow sorbent cartridge |
DE102012006884A1 (de) | 2012-04-04 | 2013-10-10 | Merck Patent Gmbh | Cyclische Amide als MetAP-2 Inhibitoren |
CN104363905A (zh) | 2012-05-08 | 2015-02-18 | 扎夫根股份有限公司 | 用metap2抑制剂治疗下丘脑性肥胖 |
EP2850079B1 (en) | 2012-05-09 | 2018-05-02 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
US9713666B2 (en) | 2013-01-09 | 2017-07-25 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
EP2968250B1 (en) | 2013-03-14 | 2019-06-19 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
US10052612B2 (en) | 2013-11-26 | 2018-08-21 | Medtronic, Inc. | Zirconium phosphate recharging method and apparatus |
US10004839B2 (en) | 2013-11-26 | 2018-06-26 | Medtronic, Inc. | Multi-use sorbent cartridge |
US10537875B2 (en) | 2013-11-26 | 2020-01-21 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
US9895477B2 (en) | 2013-11-26 | 2018-02-20 | Medtronic, Inc. | Detachable module for recharging sorbent materials with optional bypass |
US9943780B2 (en) | 2013-11-26 | 2018-04-17 | Medtronic, Inc. | Module for in-line recharging of sorbent materials with optional bypass |
US9884145B2 (en) | 2013-11-26 | 2018-02-06 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
WO2015199768A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Stacked sorbent assembly |
US10016553B2 (en) | 2014-06-24 | 2018-07-10 | Medtronic, Inc. | Replenishing urease in dialysis systems using a urease introducer |
US10124274B2 (en) | 2014-06-24 | 2018-11-13 | Medtronic, Inc. | Replenishing urease in dialysis systems using urease pouches |
WO2015199763A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | A urease introduction system for replenishing urease in a sorbent cartridge |
US10286380B2 (en) | 2014-06-24 | 2019-05-14 | Medtronic, Inc. | Sorbent pouch |
WO2015199766A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Modular dialysate regeneration assembly |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
CN114225045A (zh) | 2016-01-11 | 2022-03-25 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
US10981148B2 (en) | 2016-11-29 | 2021-04-20 | Medtronic, Inc. | Zirconium oxide module conditioning |
US11167070B2 (en) | 2017-01-30 | 2021-11-09 | Medtronic, Inc. | Ganged modular recharging system |
US10960381B2 (en) | 2017-06-15 | 2021-03-30 | Medtronic, Inc. | Zirconium phosphate disinfection recharging and conditioning |
US11213616B2 (en) | 2018-08-24 | 2022-01-04 | Medtronic, Inc. | Recharge solution for zirconium phosphate |
CA3117666A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
KR0138530B1 (ko) | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
DE69001187T2 (de) | 1989-03-06 | 1993-07-08 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
TW282399B (es) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
EP0555693B1 (en) | 1992-01-30 | 2001-09-05 | Takeda Chemical Industries, Ltd. | Method of producing highly watersoluble cyclodextrin complex |
DE69311278T2 (de) | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
US5328930A (en) | 1993-03-01 | 1994-07-12 | Emory University | Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin |
PL183378B1 (pl) | 1995-03-27 | 2002-06-28 | Assist Publ Hopitaux De Paris | Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych |
CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
WO1998005293A2 (en) | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
US6306819B1 (en) | 1997-10-31 | 2001-10-23 | Massachusetts Institute Of Technology | Method for regulating size of vascularized normal tissue |
KR100357542B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
NZ515087A (en) | 1999-04-28 | 2003-11-28 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
US6919307B2 (en) | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
CA2426703C (en) | 2000-11-01 | 2005-09-13 | Praecis Pharmaceuticals Incorporated | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
EP1379241A1 (en) | 2001-03-29 | 2004-01-14 | SmithKline Beecham Corporation | Compounds and methods |
DE60233420D1 (de) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
BR0311784A (pt) * | 2002-06-14 | 2005-03-08 | Merck & Co Inc | Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
US20040157836A1 (en) | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
EP1699812A2 (en) | 2003-12-29 | 2006-09-13 | Praecis Pharmaceuticals Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
KR100552043B1 (ko) * | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
BRPI0512856A (pt) | 2004-06-30 | 2008-04-08 | Combinatorx Inc | métodos e reagentes para o tratamento de distúrbios metabólicos |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
CA2594951A1 (en) | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
WO2006138475A2 (en) | 2005-06-16 | 2006-12-28 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
US20070254843A1 (en) | 2006-04-18 | 2007-11-01 | Praecis Pharmaceuticals Incorporated | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
US8865746B2 (en) | 2008-07-18 | 2014-10-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
CN102239149B (zh) | 2008-10-06 | 2015-05-13 | 约翰·霍普金斯大学 | 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法 |
US8906896B2 (en) | 2008-10-24 | 2014-12-09 | Ulrich Bierbach | Platinum acridine anti-cancer compounds and methods thereof |
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
WO2010065881A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
MX337575B (es) | 2009-10-09 | 2016-03-10 | Zafgen Corp | Compuestos de sulfona y métodos para lafabricación y uso de éstos. |
WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
WO2011150338A1 (en) | 2010-05-27 | 2011-12-01 | Zafgen Corporation | Methods of treating obesity |
KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
US9221787B2 (en) | 2010-10-12 | 2015-12-29 | Zafgen, Inc. | Sulphonamine compounds and methods of making and using same |
KR101892768B1 (ko) | 2010-11-09 | 2018-08-28 | 자프겐 인크. | Metap-2 저해제의 결정질 고체 및 그의 제조 및 이용 방법 |
WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
WO2012075020A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
US20130316994A1 (en) | 2010-11-29 | 2013-11-28 | Zafgen, Inc. | Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors |
WO2012075026A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of treating obesity using an effective dose of a metap-2 inhibitor |
MX344238B (es) | 2011-01-26 | 2016-12-07 | Zafgen Inc | Compuestos de tetrazol y métodos para preparar y usar los mismos. |
BR112013028534A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos |
WO2012154678A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic sulfonamide compounds and methods of making and using same |
AU2012253760B2 (en) | 2011-05-06 | 2016-02-04 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
WO2013033430A1 (en) | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
EP2850079B1 (en) * | 2012-05-09 | 2018-05-02 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
-
2011
- 2011-01-07 BR BR112012016793A patent/BR112012016793A2/pt not_active Application Discontinuation
- 2011-01-07 AU AU2011204267A patent/AU2011204267B2/en not_active Ceased
- 2011-01-07 US US13/520,736 patent/US8772333B2/en not_active Expired - Fee Related
- 2011-01-07 MX MX2012007962A patent/MX343135B/es active IP Right Grant
- 2011-01-07 CA CA2786603A patent/CA2786603C/en not_active Expired - Fee Related
- 2011-01-07 KR KR1020127020687A patent/KR101696960B1/ko active IP Right Grant
- 2011-01-07 JP JP2012548152A patent/JP5827239B2/ja not_active Expired - Fee Related
- 2011-01-07 CN CN201180008553.6A patent/CN102791699B/zh not_active Expired - Fee Related
- 2011-01-07 WO PCT/US2011/020520 patent/WO2011085201A1/en active Application Filing
- 2011-01-07 EP EP11701572.7A patent/EP2521719B1/en active Active
-
2014
- 2014-05-22 US US14/285,053 patent/US9067913B2/en not_active Expired - Fee Related
-
2015
- 2015-05-21 US US14/718,527 patent/US20160106703A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011204267B2 (en) | 2015-12-03 |
WO2011085201A1 (en) | 2011-07-14 |
CN102791699B (zh) | 2016-04-06 |
US20160106703A1 (en) | 2016-04-21 |
JP2013516484A (ja) | 2013-05-13 |
AU2011204267A1 (en) | 2012-08-02 |
US9067913B2 (en) | 2015-06-30 |
US20130018095A1 (en) | 2013-01-17 |
KR101696960B1 (ko) | 2017-01-16 |
CA2786603C (en) | 2018-02-20 |
CA2786603A1 (en) | 2011-07-14 |
BR112012016793A2 (pt) | 2018-07-31 |
EP2521719B1 (en) | 2015-07-29 |
MX2012007962A (es) | 2012-11-21 |
KR20130126880A (ko) | 2013-11-21 |
US8772333B2 (en) | 2014-07-08 |
JP5827239B2 (ja) | 2015-12-02 |
CN102791699A (zh) | 2012-11-21 |
US20150111963A1 (en) | 2015-04-23 |
EP2521719A1 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
BR112012016797A2 (pt) | intensificador dinâmico de baixo utilizando compressor com equalizador incorporado | |
WO2012103059A3 (en) | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
GB201118656D0 (en) | New compounds | |
EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
PH12015501088A1 (en) | Dimeric compounds | |
WO2010121164A3 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
WO2012103810A1 (en) | Certain chemical entities, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |